Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Synovial Sarcoma”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Testing effectiveness (Phase 2)Study completedNCT02452554
What this trial is testing

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Who this might be right for
Pleuropulmonary BlastomaRecurrent Malignant Peripheral Nerve Sheath TumorRecurrent Neuroblastoma+3 more
Children's Oncology Group 62
Testing effectiveness (Phase 2)Ended earlyNCT04145700
What this trial is testing

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Who this might be right for
Synovial Sarcoma
Eli Lilly and Company 23
Early research (Phase 1)Ended earlyNCT04176016
What this trial is testing

Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

Who this might be right for
Relapsed or Refractory Synovial Sarcoma
OncoTherapy Science, Inc. 12
Early research (Phase 1)Ended earlyNCT01469975
What this trial is testing

First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10

Who this might be right for
Sarcoma, Synovial
Centre Leon Berard 20
Testing effectiveness (Phase 2)Study completedNCT00297258
What this trial is testing

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Who this might be right for
Sarcoma, Soft Tissue
GlaxoSmithKline 148
Testing effectiveness (Phase 2)UnknownNCT00410462
What this trial is testing

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Who this might be right for
Ovarian CancerSarcomaSmall Intestine Cancer
European Organisation for Research and Treatment of Cancer - EORTC 118
Testing effectiveness (Phase 2)Study completedNCT00030667
What this trial is testing

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Who this might be right for
Childhood Desmoplastic Small Round Cell TumorChildhood Synovial SarcomaGastrointestinal Stromal Tumor+5 more
National Cancer Institute (NCI) 100
Early research (Phase 1)Study completedNCT02601937
What this trial is testing

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Who this might be right for
Rhabdoid TumorsINI1-negative TumorsSynovial Sarcoma+1 more
Epizyme, Inc. 109
Testing effectiveness (Phase 2)Study completedNCT02601950
What this trial is testing

Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Who this might be right for
Malignant Rhabdoid Tumors (MRT)Rhabdoid Tumors of the Kidney (RTK)Atypical Teratoid Rhabdoid Tumors (ATRT)+8 more
Epizyme, Inc. 267
Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+19 more
Fundación de investigación HM 25
Testing effectiveness (Phase 2)WithdrawnNCT03697824
What this trial is testing

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Who this might be right for
Neoplasms
GlaxoSmithKline
Testing effectiveness (Phase 2)Study completedNCT00831844
What this trial is testing

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Who this might be right for
Adult RhabdomyosarcomaAdult Synovial SarcomaChildhood Hepatoblastoma+13 more
National Cancer Institute (NCI) 116